Post Content
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively recent addition to the 13F portfolio of Farallon Capital. The fund first disclosed a stake in the firm in the third quarter of 2024. This position comprised 1.7 million shares. In the months since then, the hedge fund has aggressively built up this holding. Filings for the fourth quarter of 2025 show that the fund owned 9 million shares in the firm, up close to 10% compared to filings for the previous quarter. The firm operates as a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) has come in focus of elite investors since the commercial launch of Attruby for ATTR-CM, transthyretin amyloid cardiomyopathy. In the Q4 2025 earnings report, the company revealed a 35% quarter-over-quarter growth in net product revenue. Long-term data released in March showed a staggering 44.7% reduction in all-cause mortality through month 54. Hedge funds view this near-complete stabilization of the TTR protein as a significant competitive advantage over Pfizer’s legacy drug, Vyndamax. In January, BridgeBio successfully issued $632.5 million in convertible notes. This capital injection, combined with rising Attruby sales, gives the company a strong balance sheet to fund three simultaneous launches. Hedge funds prioritize companies that can scale without needing to constantly return to the equity markets for dilutive raises.
While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.